ID   604B1-B2M-KO
AC   CVCL_C1FN
SY   604B1-B2M-KO #1; 604B1-B2M-#1
DR   Wikidata; Q114310478
RX   Patent=US20200407693;
RX   PubMed=30853558;
CC   Population: Japanese.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; HGNC:914; B2M.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_DQ10 ! 604B1
SX   Male
AG   30-39Y
CA   Induced pluripotent stem cell
DT   Created: 22-09-22; Last updated: 19-12-24; Version: 5
//
RX   Patent=US20200407693;
RA   Hotta A., Xu H.-G., Kaneko S., Wang B.;
RT   "Method for producing low-antigenic cell.";
RL   Patent number US20200407693, 31-Dec-2020.
//
RX   PubMed=30853558; DOI=10.1016/j.stem.2019.02.005;
RA   Xu H.-G., Wang B., Ono M., Kagita A., Fujii K., Sasakawa N., Ueda T.,
RA   Gee P., Nishikawa M., Nomura M., Kitaoka F., Takahashi T., Okita K.,
RA   Yoshida Y., Kaneko S., Hotta A.;
RT   "Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with
RT   enhanced immune compatibility.";
RL   Cell Stem Cell 24:566-578.e7(2019).
//